US2003007928A1PendingUtilityA1

Polymer based radionuclide containing particulate material

53
Priority: Oct 25, 2000Filed: Jun 17, 2002Published: Jan 9, 2003
Est. expiryOct 25, 2020(expired)· nominal 20-yr term from priority
Inventors:Bruce Nathaniel Gray
A61P 35/00A61K 51/1255A61K 51/06A61K 51/1251A61P 1/16
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.

Claims

exact text as granted — not AI-modified
1 . A particulate material having a diameter in the range of from 5 to 200 microns comprising a polymeric matrix and stably incorporated radionuclide.  
     
     
         2 . The particulate material according to  claim 1  wherein the radionuclide is incorporated by precipitation.  
     
     
         3 . The particulate material according to  claim 1  wherein the polymeric matrix is partially cross linked.  
     
     
         4 . The particulate material according to  claim 3  wherein the polymeric matrix comprises from about 1% to about 20% cross linking.  
     
     
         5 . The particulate material according to  claim 4  wherein the polymeric matrix comprises about 4% cross linking.  
     
     
         6 . The particulate material according to  claim 1  wherein the polymeric matrix is an ion exchange resin.  
     
     
         7 . The particulate material according to  claim 6  wherein the polymeric matrix is a cation exchange resin.  
     
     
         8 . The particulate material according to  claim 6  wherein the ion exchange resin comprises a partially cross linked aliphatic polymer.  
     
     
         9 . The particulate material according to  claim 6  wherein the ion exchange resin comprises a partially cross linked polystyrene.  
     
     
         10 . The particulate material according to  claim 9  wherein the ion exchange resin comprises polystyrene partially cross linked with divinyl benzene.  
     
     
         11 . The particulate material according to  claim 1 , wherein the radionuclide is an isotope of yttrium, holmium, samarium, iodine, phosphorus, iridium or rhenium.  
     
     
         12 . The particulate material according to  claim 1 , wherein the radionuclide is yttrium-90.  
     
     
         13 . The particulate material according to  claim 1  being a microsphere.  
     
     
         14 . A particulate material having a diameter in the range of from 30 to 35 microns comprising a copolymer comprised of styrene and divinyl benzene and precipitated yttrium-90.  
     
     
         15 . A process for the production of a particulate material according to  claim 1  comprising the step of combining a polymeric matrix and a radionuclide in solution for a time and under conditions sufficient to stably incorporate the radionuclide in the matrix to produce a particulate material having a diameter in the range of from 5 to 200 microns.  
     
     
         16 . A process according to  claim 15  wherein the radionuclide is stably incorporated by precipitation into the polymeric matrix.  
     
     
         17 . A process according to  claim 15  wherein the radionuclide is yttrium-90.  
     
     
         18 . A method of radiation therapy of a patient, which comprises administration to the patient of a particulate material having a diameter in the range of from 5 to 200 microns comprising a polymeric matrix and a stably incorporated radionuclide.  
     
     
         19 . A method according to  claim 18  wherein the radionuclide is yttrium-90.  
     
     
         20 . A method according to  claim 18  wherein the radiation therapy comprises treatment of a primary or secondary liver cancer.  
     
     
         21 . Use of particulate material having a diameter in the range of from 5 to 200 microns comprising a polymeric matrix and a stably incorporated radionuclide in radiation therapy of a patient.  
     
     
         22 . Use according to  claim 21  wherein the radionuclide is yttrium-90.  
     
     
         23 . Use according to  claim 21  wherein the radiation therapy comprises treatment of a primary or secondary liver cancer.

Join the waitlist — get patent alerts

Track US2003007928A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.